Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 8/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6132473 | 0.93 | PTGS2 (0.67) | PTGS2PTGS1L3MBTL1SMN1; SMN2MAPT | |
| SCHEMBL6132192 | 0.89 | PTGS2 (0.63) | PTGS2PTGS1L3MBTL1HPGD | |
| SCHEMBL6132484 | 0.89 | PTGS2 (0.63) | PTGS2PTGS1L3MBTL1HPGD | |
| SCHEMBL6132399 | 0.87 | PTGS2 (0.58) | PTGS2PTGS1L3MBTL1SMN1; SMN2MAPT | |
| SCHEMBL6683341 | 0.87 | PTGS1 (0.58) | PTGS2PTGS1L3MBTL1HPGDSMN1; SMN2 | |
| SCHEMBL6681240 | 0.86 | PTGS2 (0.60) | PTGS2PTGS1L3MBTL1 | |
| SCHEMBL28957164 | 0.85 | SMN1; SMN2 (0.54) | PTGS1SMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL5204715 | 0.84 | PTGS2 (0.58) | PTGS2PTGS1L3MBTL1 | |
| SCHEMBL6885231 | 0.84 | PTGS2 (0.58) | PTGS2PTGS1L3MBTL1 | |
| SCHEMBL6132400 | 0.83 | PTGS2 (0.57) | PTGS2PTGS1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019144-B2 | 1,2,4-Triazole derivative, method for preparing the same, and pharmaceutical composition containing the same | CJ CORP. (KR) | 2006-03-28 | — | — | US | disclosed |
| US-20050075507-A1 | 1,2,4-Triazole derivative, method for preparing the same, and pharmaceutical composition containing the same | CJ CHEILJEDANG CORPORATION (KR) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075507-A1 | 1,2,4-Triazole derivative, method for preparing the same, and pharmaceutical composition containing the same | CYP4B1, CYP3A5, CYP7A1 | PTGS2 1769/4885PTGS1 523/4885L3MBTL1 4445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.